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The direct oral anticoagulants (DOAC), which include the thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, apixaban and edoxaban, are in clinical use in many countries (Fig 1) . Clinical trials have shown that DOAC, unlike vitamin-K antagonists (VKA), are effective/safe when administered without dose-adjustment based on labtesting. 1 However, it is a misconception to believe that the laboratory will not have a role in the management of patients treated with DOAC. This review is aimed at discussing
• The situations where the laboratory may help clinicians with decision-making in the management of treated patients.
• The most appropriate tests to be used
• The interpretation of results

NEED FOR TESTING
Although the experience is still limited one may identify situations when the laboratory measurement for DOAC is potentially useful and others that would require further evaluation (Table 1) .
Potentially useful
• At baseline. Laboratory (and clinical) evaluation is useful for excluding an underlying bleeding tendency, renal insufficiency and to determine if the test(s) that will be used for measuring the drug effect is (are) normal at baseline. Beside the prothrombin and partial thromboplastin times (PT, APTT), other tests to be included are blood cell-counts and others that will depend on which drug is used for treatment (see below). Assessment of creatinine clearance is of paramount importance as DOAC are largely excreted via the kidney. 1 Therefore, even mild renal insufficiency may lead to drug accumulation during treatment, thus increasing the bleeding risk. Assessment of creatinine clearance is indicated not only before
For personal use only. on . by guest www.bloodjournal.org From starting, but also at regular intervals during treatment as kidney function may deteriorate rapidly, especially in the elderly.
• Pre-operatively. Owing to their short half-life, the effect of DOAC may be rapidly dissipated by discontinuation of the treatment before surgical/invasive procedures.
However, there may be patients with mild, perhaps unrecognized renal insufficiency in whom the clearance may be delayed. 2 
Others
• Coagulation tests might be considered upon attainment of stable anticoagulation (1-2 weeks after initiation) to provide the level of the anticoagulation achieved chronically. This information might be useful to interpret subsequent results.
• Drug anticoagulant levels could be measured occasionally at the time of medical visits to assess adherence to treatment. However, it should be realized that given the short DOAC half-life (8-15hours), a dose missed a few days earlier than testing might not be detected in the laboratory.
• Since DOAC may interact with other drugs 6 , comparison of their anticoagulant effects measured before and after introduction of additional drugs may help to confirm the degree of known drug-to-drug interactions or to unravel unknown interactions.
• DOAC are prescribed at fixed dosage, hence individuals with extreme body weights may benefit from dose adjustment to avoid under-or over-anticoagulation. This issue was not evaluated in phase III trials and warrants assessment when DOAC will be used in real life. Information based on laboratory testing and clinical events recorded during treatment could help for decision making in these patients.
WHICH TEST(S) FOR WHICH DRUG
The following sections are aimed at discussing the choice of tests for the currently available drugs. The choice is based on the limited experience and literature data accumulated to date and on the following practical considerations.
• Prompt test availability
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• Linearity and adequacy of test response to increasing dosage • Amenability to standardization (i.e.,comparability of results between laboratories using the same method, but different reagents). Standardization is mandatory for patients on VKA, but it is also important for DOAC. Assuming that future clinical studies will determine specific cut-off values able to alert clinicians to bleeding risk, these values could be generalized to all laboratories, regardless of the reagent used for testing, only if the tests are standardized.
Dabigatran
Dabigatran prolongs the clotting times of tests based on thrombin generation and fibrinogen-to-fibrin conversion. Among them, the most promising are the thrombin and ecarin clotting times (TT and ECT). 7 TT reflects fibrinogen-to-fibrin conversion and is performed by measuring plasma clotting times upon addition of thrombin. TT is readily available in most laboratories; the clotting time prolongation is linearly and dose dependently related to dabigatran concentrations. 8 However, responsiveness to increasing dosage is excessive: TT prolongations induced by the typical 175ng/mL dabigatran plasma concentration (observed in patients taking 150mg twice-daily) 9,10 may be 10-times the baseline value. 8 Hence, a normal TT should rule out dabigatran anticoagulant effect, but the degree of prolongation poorly reflects drug concentration. Recently, a dilute-TT adequately responsive to dabigatran (i.e.,prolongation up to 2-times the baseline value at 175ng/mL dabigatran) ( Table 2 ) has become available and may be used for dabigatran measurement. [11] [12] Ecarin is a commercially available snake-venom that converts FII into meizothrombin. The dabigatran induced inhibition of meizothrombin is measured by synthetic substrates or clotting assays. 13 ECT proved linearly and dose dependently related to dabigatran
prolongations induced by 175ng/mL amount to 3-times the baseline value 8 (Table 2) . Presently, ECT is not readily available in most laboratories, but could be easily implemented in many coagulation platforms.
13,14
The APTT is another test that can be used for dabigatran; the APTT prolongation in response to 175ng/mL dabigatran amounts to 1.7-times the baseline value, but is not linearly-related to the concentration. 8 Furthermore, the between-reagent variability associated with the APTT, makes the interpretation of results obtained with one reagent not necessarily applicable to others. The PT is relatively insensitive to dabigatran 8 and
should not be used for this drug.
In summary, the dilute-TT or ECT are the tests of choice for dabigatran. The first is readily available even in emergency and can be easily implemented in all coagulometers. The second (although not yet widely available) could become available in clinical laboratories as the ecarin-venom is commercially available. Both dilute-TT and ECT are fairly responsive to dabigatran 8 and might be easier than the APTT to standardize.
Rivaroxaban
Rivaroxaban inhibits FXa and prolongs the clotting times of tests assessing coagulation downstream from FXa. Among them, the most promising are the anti-FXa and PT tests. Anti-FXa is based on the measurement of residual-FXa with synthetic substrates upon mixing plasma with FXa. This test, presently used for low molecular weight heparins, has been modified to be fairly responsive to rivaroxaban. 15 For personal use only. on June 13, 2017. by guest www.bloodjournal.org From PT prolongations are adequate to detect rivaroxaban activity within the range of concentrations observed in treated patients. 16 On average, PT is prolonged 1.5-times the baseline value at 215ng/mL rivaroxaban 16 (i.e.,the plasma concentration observed in patients taking 20mg once-daily) 17 (Table 2) . Hence, prolongations are greater in patients who have received an overdose of the drug.
In summary, the PT or the anti-FXa assay can be used for patients on rivaroxaban.
However, the anti-FXa is not readily available in most laboratories, especially at night.
Moreover, standardization as assessed in a collaborative survey, is poor: the average inter-laboratory variation of results obtained while measuring the same rivaroxaban-spiked plasmas by means of local methods was high (i.e.,25%). 18 Conversely, the PT is readily available even in emergency and its standardization could be obtained as described 19, 20 by expressing results as PT-ratio (patient-to-normal) corrected by means of a sensitivity index. Such an index can be determined for working thromboplastins relative to an international standard. The INR (used for VKA) should not be used for rivaroxaban because it increases the drug induced between-thromboplastin variability.
19
Apixaban
Limited experience is available for apixaban and laboratory testing. While the PT is in general poorly responsive, the anti-FXa assay proved highly correlated and adequately responsive to the apixaban plasma concentrations. 21 The problems of availability and standardization of the anti-FXa assay discussed above for rivaroxaban also apply to apixaban.
9
TIMING OF TESTING
Onset/offset actions of DOAC are relatively fast. Peak plasma levels are reached 2 hours after ingestion of dabigatran 8, 10 or rivaroxaban. 17 Rivaroxaban plasma concentration (in patients taking 20mg once-daily) is as low as 32ng/mL 17 at 24 hours and dabigatran plasma concentration (in patients taking 150mg twice-daily) is reduced to 91ng/mL after 12 hours 10 ( Table 2) . Consequently, the interpretation of test results is heavily dependent on the timing of blood sampling. It is still unclear whether the peak or trough drug concentration should be evaluated when the choice of timing for blood drawing is feasible. 
EXPRESSION OF RESULTS
Results
ALERT VALUES
Test values able to alert clinicians to bleeding or thrombotic risk have not yet been established because the experience to date is based mainly on normal plasma spiked invitro with increasing amounts of each DOAC. Accurate determination of alert values requires clinical observations in treated patients combined with standardized laboratory testing and will be undertaken when DOAC are more widely used.
For
DOAC EFFECT ON COMMON HEMOSTATIC PARAMETERS
Owing to their mode of action it is anticipated that DOAC affect the measurement of some of the most common hemostatic parameters. Here some examples:
• Antithrombin activity is overestimated in patients on rivaroxaban or dabigatran when the target enzyme used for testing is FXa or thrombin, respectively. 22, 23 This can be avoided using as target enzymes FXa or thrombin when the drug used for treatment is dabigatran or rivaroxaban, respectively.
• Fibrinogen, when measured as clotting activity is underestimated in patients on dabigatran. 23 The degree of underestimation is reagent dependent and is likely due to different types/concentrations of thrombin used for testing.
• Tests for activated protein C (APC) resistance may be affected by DOAC when testing is based on paired APTT with/without APC. 23, 24 Because of this effect, plasmas from heterozygous FV Leiden carriers might resemble wild types when patients are treated with DOAC.
23,24
• FXIII when measured by chromogenic substrates may be underestimated in patients on dabigatran 25 , simply because FXIII is activated by thrombin.
• Although few data are available, it is possible that measurements of proteins C/S, performed with clotting techniques 26 , individual coagulation factors 26, 27 and the search for lupus anticoagulants 28 , may also be affected by DOAC.
All the above considerations point to conclude that caution should be exerted in the interpretation of results of hemostatic parameters measured for patients on DOAC.
CONCLUSIONS
Although DOAC do not require laboratory testing for dose adjustment, there are occasions when laboratory investigations may be useful. Many tests can be used and the choice should be primarily based on their prompt availability. In the future there will be millions of 
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Potentially useful
• At baseline (before initiation of treatment)
• Before surgical/invasive procedures
• During adverse events (hemorrhage or thrombosis)
• Need for immediate reversal of anticoagulation
Others
• When chronic anticoagulation is achieved (1-2 weeks after initiation)
• During clinical visits
• Soon before and after introducing additional drugs
• Low or high body weight 32 ng/mL (6-239 ng/mL) a Steady-state geometric mean dabigatran plasma concentration (25th-75th percentile range) measured around 2 (C peak ) or 12 hours (C trough ) after 150mg dabigatran administration twice-daily. 10 Dilute thrombin clotting time (dTT) or ecarin clotting time (ECT) at C peak are approximately prolonged 2-or 3-times the baseline value, respectively. 8 Between-reagent variability should be considered when interpreting results. b Steady-state geometric mean rivaroxaban plasma concentration (90% prediction interval) measured around 2 (C peak ) or 24 hours (C trough ) after 20mg rivaroxaban administration once-daily. 17 Prothrombin time (PT) at C peak is approximately prolonged 1.5-times the baseline value 16, 19 . Between-reagent variability should be considered when interpreting results. 16, 19, 26, 30 For personal use only. on . by guest www.bloodjournal.org From
